Holen Kyle D相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

EGFR生物标志物检测方法的比较：对胶质母细胞瘤患者精准医疗的意义

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-18-3034

Lassman, Andrew B; Roberts-Rapp, Lisa; Sokolova, Irina; Song, Minghao; Pestova, Ekaterina; Kular, Rupinder; Mullen, Carolyn; Zha, Zheng; Lu, Xin; Gomez, Erica; Bhathena, Anahita; Maag, David; Kumthekar, Priya; Gan, Hui K; Scott, Andrew M; Guseva, Maria; Holen, Kyle D; Ansell, Peter J; van den Bent, Martin J

细胞生物学

发表日期：2019

文献求助收藏

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

Enavatuzumab（一种靶向TWEAK受体的首创人源化单克隆抗体）治疗晚期实体瘤患者的I期研究

期刊:Molecular Cancer Therapeutics

影响因子:5.5

doi:10.1158/1535-7163.MCT-17-0330

Lam, Elaine T; Eckhardt, S Gail; Messersmith, Wells; Jimeno, Antonio; O'Bryant, Cindy L; Ramanathan, Ramesh K; Weiss, Glen J; Chadha, Manpreet; Oey, Abbie; Ding, Han Ting; Culp, Patricia A; Keller, Stephan F; Zhao, Vivian Y; Tsao, L Claire; Singhal, Anil; Holen, Kyle D; Von Hoff, Daniel

单克隆抗体

发表日期：2018

文献求助收藏

Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study

维利帕尼联合全脑放射治疗治疗非小细胞肺癌脑转移患者：一项随机、全球、安慰剂对照研究的结果

期刊:Journal of Neuro-Oncology

影响因子:3.1

doi:10.1007/s11060-016-2275-x

Chabot, Pierre; Hsia, Te-Chun; Ryu, Jeong-Seon; Gorbunova, Vera; Belda-Iniesta, Cristobal; Ball, David; Kio, Ebenezer; Mehta, Minesh; Papp, Katherine; Qin, Qin; Qian, Jane; Holen, Kyle D; Giranda, Vince; Suh, John H

细胞生物学

发表日期：2017

文献求助收藏

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

depatuxizumab mafodotin (ABT-414) 单药治疗 EGFR 扩增复发性胶质母细胞瘤患者的疗效：一项多中心国际研究的结果

期刊:Cancer Chemotherapy and Pharmacology

影响因子:2.3

doi:10.1007/s00280-017-3451-1

van den Bent, Martin; Gan, Hui K; Lassman, Andrew B; Kumthekar, Priya; Merrell, Ryan; Butowski, Nicholas; Lwin, Zarnie; Mikkelsen, Tom; Nabors, Louis B; Papadopoulos, Kyriakos P; Penas-Prado, Marta; Simes, John; Wheeler, Helen; Walbert, Tobias; Scott, Andrew M; Gomez, Erica; Lee, Ho-Jin; Roberts-Rapp, Lisa; Xiong, Hao; Bain, Earle; Ansell, Peter J; Holen, Kyle D; Maag, David; Reardon, David A

细胞生物学

发表日期：2017

文献求助收藏

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors

组蛋白去乙酰化酶抑制剂帕比司他治疗低级别神经内分泌肿瘤患者的II期临床试验

期刊:Oncologist

影响因子:4.2

doi:10.1634/theoncologist.2016-0060

Jin, Ning; Lubner, Sam J; Mulkerin, Daniel L; Rajguru, Saurabh; Carmichael, Lakeesha; Chen, Herb; Holen, Kyle D; LoConte, Noelle K

发表日期：2016

文献求助收藏

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors

一项针对难治性实体瘤的γ-分泌酶抑制剂RO4929097联合卡培他滨的多中心I期研究

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-014-0166-6

LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy; Tevaarwerk, Amye; Leverence, Rachael; Kolesar, Jill; Siu, Lillian; Lubner, Sam J; Mulkerin, Daniel L; Schelman, William R; Deming, Dustin A; Holen, Kyle D; Carmichael, Lakeesha; Eickhoff, Jens; Liu, Glenn

发表日期：2015

文献求助收藏

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study

一项针对晚期胰腺癌和胆道癌患者的索拉非尼、奥沙利铂和2天高剂量卡培他滨I期研究：威斯康星肿瘤网络研究

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-012-9916-5

LoConte, Noelle K; Holen, Kyle D; Schelman, William R; Mulkerin, Daniel L; Deming, Dustin A; Hernan, Hilary R; Traynor, Anne M; Goggins, Timothy; Groteluschen, David; Oettel, Kurt; Robinson, Emily; Lubner, Sam J

发表日期：2013

文献求助收藏

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

一项针对晚期恶性肿瘤患者的伏立诺他联合硼替佐米治疗的I期研究

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-013-0029-6

Schelman, William R; Traynor, Anne M; Holen, Kyle D; Kolesar, Jill M; Attia, Steven; Hoang, Tien; Eickhoff, Jens; Jiang, Zhisheng; Alberti, Dona; Marnocha, Rebecca; Reid, Joel M; Ames, Matthew M; McGovern, Renee M; Espinoza-Delgado, Igor; Wright, John J; Wilding, George; Bailey, Howard H

发表日期：2013

文献求助收藏

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.

Vorinostat 与硼替佐米联合用于晚期恶性肿瘤患者，可直接改变靶基因的转录

期刊:Cancer Chemotherapy and Pharmacology

影响因子:2.3

doi:10.1007/s00280-013-2242-6

Kolesar Jill M, Traynor Anne M, Holen Kyle D, Hoang Tien, Seo Songwon, Kim Kyungmann, Alberti Dona, Espinoza-Delgado Igor, Wright John J, Wilding George, Bailey Howard H, Schelman William R

发表日期：2013

文献求助收藏

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

贝伐珠单抗联合厄洛替尼治疗晚期肝细胞癌患者的II期研究

影响因子:5.1

doi:10.1002/cncr.26556

Philip, Philip A; Mahoney, Michelle R; Holen, Kyle D; Northfelt, Donald W; Pitot, Henry C; Picus, Joel; Flynn, Patrick J; Erlichman, Charles

细胞生物学

发表日期：2012

文献求助收藏